Canada markets closed
  • S&P/TSX

    21,284.84
    +68.69 (+0.32%)
     
  • S&P 500

    4,566.48
    +21.58 (+0.47%)
     
  • DOW

    35,741.15
    +64.13 (+0.18%)
     
  • CAD/USD

    0.8075
    -0.0016 (-0.20%)
     
  • CRUDE OIL

    83.47
    -0.29 (-0.35%)
     
  • BTC-CAD

    77,699.70
    +2,136.66 (+2.83%)
     
  • CMC Crypto 200

    1,504.89
    +1,262.21 (+520.11%)
     
  • GOLD FUTURES

    1,807.90
    +11.60 (+0.65%)
     
  • RUSSELL 2000

    2,312.64
    +21.37 (+0.93%)
     
  • 10-Yr Bond

    1.6350
    -0.0200 (-1.21%)
     
  • NASDAQ

    15,226.71
    +136.51 (+0.90%)
     
  • VOLATILITY

    15.18
    -0.25 (-1.62%)
     
  • FTSE

    7,222.82
    +18.27 (+0.25%)
     
  • NIKKEI 225

    28,600.41
    -204.44 (-0.71%)
     
  • CAD/EUR

    0.6951
    +0.0009 (+0.13%)
     

Heat Biologics to Provide Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Conference call scheduled for September 2nd at 11:00 AM ET

DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will host a conference call on Thursday, September 2nd at 11:00 A.M. Eastern Time to provide an update on the Company’s activities.

The conference call may be accessed by dialing 844-602-0380 for U.S. callers or +1 862-298-0970 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2768/42602 or on the Company’s website at https://ir.heatbio.com/.

An audio replay of the call will be available through September 16, 2021, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 42602.

About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

For more information, please visit: www.heatbio.com, and also follow us on Twitter.

Media and Investor Relations Contact
David Waldman
+1 919 289 4017
investorrelations@heatbio.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting